Atrial Fibrillation
Conditions
Keywords
atrial fibrillation, protein microarray, proteomic biomarkers, PV dependent atrial fibrillation
Brief summary
The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses. The aim of this study is to reveal the specific biomarkers by antibody microarrays.
Detailed description
One hundred twenty patients with atrial fibrillation will participate in the study. They will be divided into three groups. 1. Patients with AF recurrence after the first procedure but with isolated pulmonary veins at the beginning of the second AF ablation b)patients with AF recurrence after repeat PV ablation. 2. Patients with PV-associated atrial fibrillation. The group will be included patients with freedom of atrial fibrillation after PV isolation (first or repeat procedure). 3. Healthy volunteers Groups would be formed from patients who previously underwent atrial fibrillation ablations and whose blood samples have been taken and placed in a biobank before interventional treatment. The first step will include proteomic serum profiling using antibody microarrays in ten subjects will be split into 3 groups. The second step will include validation of selected protein biomarkers, in the total cohort (N=120).
Interventions
DIAGNOSTIC_TESTProteomic analysis by antibody microarrays
Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
Sponsors
National Medical Research Center for Therapy and Preventive Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
• Patient with paroxysmal/persistent atrial fibrillation who underwent interventional treatment
Exclusion criteria
* permanent AF * contraindications to oral anticoagulation or heparin * chronic kidney disease requiring dialysis * untreated hypo- or hyperthyroidism * breast feeding * pregnancy * chronic kidney disease requiring dialysis * decompensated heart failure * stroke within the last 3 months * myocardial infarction within the last 3 months * Percutaneous coronary intervention or Coronary Artery Bypass Grafting within the last 3 months * active myocarditis * artificial valve replacement surgery * severe mitral or aortic stenosis * coronary artery disease requiring revascularization * heart transplant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proteins after validation | 1 year | number of protein which will be specific for non-PV associated arrhythmic focuses group after validation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| proteins after screening | 1 year | number of protein which will be specific for non-PV associated arrhythmic focuses group after screening |
Countries
Russia
Outcome results
None listed